期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

血管内皮细胞生长因子及其受体在强直性脊柱炎患者中的表达及研究 被引量：9

下载PDF
导出
摘要 强直性脊柱炎（Ankylosing Spondylitis,AS）是一种慢性病程,以侵犯中轴关节为主,为类风湿因子阴性的脊柱关节病,属于自身免疫性疾病,好发于16-30岁的青年。血管内皮细胞生长因子（vascular endothelial growth factor,VEGF）是一种强烈的丝裂原,同时也是血管生成激活分子,
作者 马莉 张育 汪中强 顾健
机构地区 苏北人民医院扬州市血液学研究所
出处 《中国实验诊断学》 北大核心 2011年第2期351-352,共2页 Chinese Journal of Laboratory Diagnosis
基金 江苏省扬州市科技局(2006057)
关键词 血管内皮细胞生长因子 强直性脊柱炎 类风湿因子阴性 自身免疫性疾病 患者 受体 脊柱关节病 慢性病程
分类号 R593.23 [医药卫生—内科学]
  • 相关文献

参考文献6

  • 1Vanderlinden SJ,Valkenburg HA,Cats A.Evaluation of diagnostic criteria for ankylosing spondylitis.A proposal for the New York criteria[J].Arthritis Rheum,1984,27(4):361.
  • 2Ferrara M,Henael WJ.Pituitary follicular cells secretea novelh eparin-binding growth factor specific for vascular endothelial cells[J].Biochem Biophys Res Commun,1989,161(2):851.
  • 3Yoon YS,Johnson IA,Park JS,et a l.Therapeutic myocardiala ngiogenesis with vascular endothelial growth factor[J].Mol Cell Biochem,2004,264(1/2):63.
  • 4倪效,燕敏.VEGF受体功能研究进展[J].生命科学,2008,20(1):120-124. 被引量：24
  • 5王哲,王全平,张俊华,李靖,吕荣.骨形成蛋白在黄韧带骨化中的表达定位[J].第四军医大学学报,2002,23(4):341-343. 被引量：22
  • 6Carmeliet P,Moons L,Luttun A,et al.Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions[J].Nat Med,2001,7(5):575.

二级参考文献38

  • 1Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci. (Lond),2005, 109(3): 227-41
  • 2Suto K, Yamazaki Y, Morita T, et al Crystal structures of novel vascular endothelial growth factors (VEGF) from snake venoms: insight into selective VEGF binding to kinase insert domain containing receptor but not to fms-like tyrosine kinase-1. J Biol Chem, 2005, 280(3): 2126-31
  • 3Muller YA, Li B, Christinger HW, et al. Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. Proc Natl Acad Sci USA, 1997, 94(14): 7192-7
  • 4De Falco S, Gigante B, Persico MG. Structure and function of placental growth factor. Trends Cardiovasc Med, 2002, 12(6): 241-6
  • 5Woolard J, Wang WY, Bevan HS, et al. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res, 2004, 64(21): 7822-35
  • 6Lee S, Jilani SM, Nikolova GV, et al. Processing of VEGFA by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol, 2005, 169(4): 681-91
  • 7Christinger HW, Fuh G, de Vos AM, et al. The crystal structure of placental growth factor in complex with domain 2 of vascular endothelial growth factor receptor-1. J Biol Chem, 2004, 279(11): 10382-8
  • 8Gallicchio M, Mitola S, Valdembri D, et al. Inhibition of vascular endothelial growth factor receptor 2-mediated endothelial cell activation by Axl tyrosine kinase receptor. Blood,2005, 105(5):1970-6
  • 9Guo DQ, Wu LW, Dunbar JD, et al. Tumor necrosis factor employs a protein-tyrosine phosphatase to inhibit activation of KDR and vascular endothelial cell growth factorinduced endothelial cell proliferation. J Biol Chem, 2000, 275(15): 11216-21
  • 10Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature,1996,380(6573): 435-9

共引文献44

同被引文献109

引证文献9

二级引证文献50

中国实验诊断学
2011年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部